Symbolbild · KI-generiert
HLS Therapeutics Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products that address unmet needs in the treatment of psychiatric disorders and cardiovascular disease. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.
Company description as published by the issuer via TMX Money.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| HLS Therapeutics Inc. | HLS | TSX | 94 Mio. USD |
| Grown Rogue International Inc. | GRIN | CSE | 94 Mio. USD |
| Zentek Ltd. | ZEN | TSXV | 86 Mio. USD |
| Invesque Inc. | IVQ | TSX | 85 Mio. USD |
| Rallybio | RLYB | NASDAQ | 84 Mio. USD |
| Enablence Technologies Inc. | ENA | TSXV | 83 Mio. USD |
| Jushi Holdings Inc. Class B Subordinate Voting Shares | JUSH | CSE | 83 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.